



Pear Therapeutics Inc (A): Constituent Addition (Russell U.S. Index Series)

01 August 2022

Following a review of PEAR Therapeutics Inc (A) (PEAR) exclusion from the June 2022 annual rebalance of the Russell US Index Series due to failing the minimum free float and voting rights requirements, FTSE Russell has determined that PEAR did satisfy the minimum 5% free float and voting rights requirements on the rank date, based on confirmatory statements included within publicly available documents (i.e. within the 8-K filed on November 2021). As a result, FTSE Russell has concluded that PEAR Therapeutics is eligible for inclusion to the Russell US Index Series and it will be added in conjunction with the September 2022 quarterly review (effective on the open of Monday, September 19th), in accordance with the [FTSE Russell Correction Guidelines](#).

New Membership - R2000, R2500, RSCC, R3000, Microcap

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1440
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2022 FTSE Russell